Immix Biopharma, Inc. Annual Operating Income (Loss) in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Immix Biopharma, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2020 to 2023.
  • Immix Biopharma, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$4.7M, a 26.4% decline year-over-year.
  • Immix Biopharma, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$20.2M, a 74.5% decline year-over-year.
  • Immix Biopharma, Inc. annual Operating Income (Loss) for 2023 was -$16.1M, a 96.4% decline from 2022.
  • Immix Biopharma, Inc. annual Operating Income (Loss) for 2022 was -$8.22M, a 508% decline from 2021.
  • Immix Biopharma, Inc. annual Operating Income (Loss) for 2021 was -$1.35M, a 198% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$16.1M -$7.92M -96.4% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-29
2022 -$8.22M -$6.87M -508% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-29
2021 -$1.35M -$898K -198% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-27
2020 -$454K Jan 1, 2020 Dec 31, 2020 10-K 2022-03-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.